Vancomycin-associated drug-induced hypersensitivity syndrome - 21/06/19
Abstract |
Background |
Although hypersensitivity reactions are well characterized for certain medications, vancomycin-associated drug-induced hypersensitivity syndrome (DIHS), or drug reaction with eosinophilia and systemic symptoms (DRESS), has yet to be defined.
Objective |
To better define the clinical phenotype of vancomycin-associated DIHS.
Methods |
A retrospective case series was conducted over an 8-year period at a single, academic institution. A total of 29 cases of DIHS/DRESS were identified, of which 4 were attributed to vancomycin. A literature review was performed; it identified 28 additional cases of vancomycin-induced DIHS. Vancomycin-associated acute interstitial nephritis was also reviewed to detect additional, previously uncharacterized cases of systemic hypersensitivity. The review yielded 11 additional cases.
Results |
In this literature review and retrospective series, the incidence of renal dysfunction among vancomycin-induced cases (75% and 68% of cases in the series and literature, respectively) was notably higher than the overall reported incidence in DIHS (10%-40%). The degree of renal impairment was also significantly increased in the retrospective series (a median 4.98-fold change in baseline creatinine level vs a 2.25-fold increase in non–vancomycin-associated cases [P = .011]).
Limitations |
The principal limitation of this study is the small sample size. Other notable limitations include the retrospective nature of the study and absence of confirmatory renal biopsies.
Conclusion |
Although the current understanding of DIHS/DRESS is imperfect, our findings suggest that vancomycin-induced cases present with a unique phenotype characterized by a higher burden of renal involvement.
Le texte complet de cet article est disponible en PDF.Key words : DIHS, DRESS, drug reaction with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome, renal dysfunction, vancomycin
Abbreviations used : AIN, DIHS, DRESS
Plan
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
Vol 81 - N° 1
P. 123-128 - juillet 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?